Full results & analysis
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pembrolizumab and Tazemetostat Following ASCT or CAR T-Cell Therapy in Aggressive B-Cell Non-Hodgkin's Lymphoma
NCT06242834Phase 2
Key facts
- Status
- Active, not recruiting
- Start
- Sep 2024
- Primary completion
- Apr 2027
- Countries
- 1
- Sponsor
- Northwestern University
- Modality
- Immune Checkpoint Inhibitors, Recombinant Proteins and Enzymes, Small Molecules
- Conditions
- B-cell non-Hodgkin lymphoma
01
Overview
Phase 2, open-label, single-arm trial of pembrolizumab and tazemetostat in B-cell non-Hodgkin lymphoma, sponsored by Northwestern University. Primary endpoint: Event-Free Survival at 6 months. Started Sep 2024; status: active, not recruiting.
02
Design
1 arm- Study design
- Non-randomizedOpen-labelSingle group
Treatment (pembrolizumab, tazemetostat)
Pembrolizumab IV + Tazemetostat PO
03
Who it enrols
Adult patients with aggressive B-cell NHL intended for or currently undergoing standard of care ASCT or CAR T-cell therapy, with ECOG 0-1, adequate organ function, and no prior PD-1/PD-L1 or EZH2 inhibitor therapy.
04
Endpoints
Primary
Event-Free Survival
Secondary
Progression-Free Survival
Overall Survival
Incidence of Adverse Events
Objective Response Rate
Complete Response Rate
Partial Response Rate
Beyond the preview
Go deeper on NCT06242834.
Full results, competitive context and analysis are in the Gosset platform.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06242834.